Publicacións en colaboración con investigadores/as de University of Glasgow (3)

2022

  1. Biomarker-based assessment of collagen cross-linking identifies patients at risk of heart failure more likely to benefit from spironolactone effects on left atrial remodelling. Insights from the HOMAGE clinical trial

    European Journal of Heart Failure, Vol. 24, Núm. 2, pp. 321-331

2019

  1. Potential spironolactone effects on collagen metabolism biomarkers in patients with uncontrolled blood pressure

    Heart, Vol. 105, Núm. 4, pp. 307-314

2018

  1. Biomarker-based phenotyping of myocardial fibrosis identifies patients with heart failure with preserved ejection fraction resistant to the beneficial effects of spironolactone: results from the Aldo-DHF trial

    European Journal of Heart Failure, Vol. 20, Núm. 9, pp. 1290-1299